Astrazeneca Pharma India Ltd
ASTRAZENAstrazeneca Pharma India Ltd
ASTRAZEN![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/smallcap.png)
![](https://assets.tickertape.in/sector-icons/high_risk.png)
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
173.68 | 23.39 | 0.36% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.93 | 6.39 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
AstraZeneca Pharma India Limited is a biopharmaceutical company engaged in the discovery, development and commercialization of medicines for core areas of healthcare.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 570.50 | 558.10 | 583.25 | 744.58 | 844.80 | 826.40 | 820.36 | 1,029.07 | 1,346.76 | 1,439.05 | ||||||||||
Raw Materials | 193.65 | 155.96 | 231.52 | 232.51 | 344.44 | 292.00 | 297.49 | 408.84 | 628.33 | 1,289.86 | ||||||||||
Power & Fuel Cost | 7.43 | 7.68 | 8.30 | 8.27 | 7.72 | 7.37 | 8.10 | 5.54 | 4.87 | |||||||||||
Employee Cost | 169.35 | 162.04 | 150.39 | 197.40 | 216.70 | 219.54 | 230.21 | 259.10 | 241.45 | |||||||||||
Selling & Administrative Expenses | 154.91 | 144.27 | 168.54 | 198.14 | 157.18 | 129.72 | 145.09 | 185.72 | 234.33 | |||||||||||
Operating & Other expenses | 21.98 | 36.82 | -34.04 | 20.67 | -14.93 | 29.46 | 38.53 | 18.88 | 2.10 | |||||||||||
EBITDA | 23.18 | 51.33 | 58.54 | 87.59 | 133.69 | 148.31 | 100.94 | 150.99 | 235.68 | 149.19 | ||||||||||
Depreciation/Amortization | 17.43 | 15.83 | 14.74 | 14.92 | 18.58 | 20.13 | 16.95 | 16.26 | 14.94 | 15.04 | ||||||||||
PBIT | 5.75 | 35.50 | 43.80 | 72.67 | 115.11 | 128.18 | 83.99 | 134.73 | 220.74 | 134.15 | ||||||||||
Interest & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 1.14 | 1.09 | 0.95 | 0.63 | 1.20 | 1.15 | ||||||||||
PBT | 5.75 | 35.50 | 43.80 | 72.67 | 113.97 | 127.09 | 83.04 | 134.10 | 219.54 | 133.00 | ||||||||||
Taxes & Other Items | 0.50 | 15.45 | 17.89 | 18.22 | 41.76 | 33.79 | 21.44 | 34.81 | 58.03 | 37.11 | ||||||||||
Net Income | 5.25 | 20.05 | 25.91 | 54.45 | 72.21 | 93.30 | 61.60 | 99.29 | 161.51 | 95.89 | ||||||||||
EPS | 2.10 | 8.02 | 10.36 | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.60 | 38.36 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 2.00 | 10.00 | 16.00 | 24.00 | 16.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.05 | 0.41 | 0.40 | 0.37 | 0.42 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Astrazeneca Pharma India Ltd | 103.11 | 23.39 | 0.36% |
Sun Pharmaceutical Industries Ltd | 45.08 | 6.43 | 0.75% |
Cipla Ltd | 31.71 | 4.88 | 0.80% |
Torrent Pharmaceuticals Ltd | 70.18 | 16.95 | 0.82% |
Price Comparison
Compare ASTRAZEN with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 1.22%
Top 5 Mutual Funds holding Astrazeneca Pharma India Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Nippon India Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.6007% | Percentage of the fund’s portfolio invested in the stock 0.77% | Change in the portfolio weight of the stock over the last 3 months 0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/226 (+7) |
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Plan Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5204% | Percentage of the fund’s portfolio invested in the stock 2.10% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 13/49 (0) |
ICICI Prudential Smallcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5046% | Percentage of the fund’s portfolio invested in the stock 1.00% | Change in the portfolio weight of the stock over the last 3 months 0.13% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 72/107 (-1) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
Increasing Dividends
ASTRAZEN has increased dividends consistently over the last 5 years
Dividend Yield
Current dividend yield is 0.36%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.60 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 5, 2024
Dividend/Share
₹24.00
Ex DateEx Date
Jul 5, 2024
Cash Dividend
Ex DateEx DateJul 14, 2023
Dividend/Share
₹16.00
Ex DateEx Date
Jul 14, 2023
Cash Dividend
Ex DateEx DateJul 7, 2022
Dividend/Share
₹8.00
Ex DateEx Date
Jul 7, 2022
Cash Dividend
Ex DateEx DateAug 18, 2021
Dividend/Share
₹2.00
Ex DateEx Date
Aug 18, 2021
Cash Dividend
Ex DateEx DateAug 20, 2020
Dividend/Share
₹2.00
Ex DateEx Date
Aug 20, 2020
Revenue from operations jumped 31.15% year on year (YoY) to Rs 387.52 crore in the quarter ended 30 June 2024, by increase in demonstrating company's focus on improving access to patients. Profit before exceptional items and tax stood at Rs 42.4 crore in first quarter of FY25, down 40.62% from Rs 71.4 crore posted in Q1 FY24. The firm reported exceptional loss of Rs 57.56 crore during the quarter. Total expenses spiked 52.25% YoY to Rs 353.47 crore in Q1 FY25. Cost of material consumed was at Rs 45.85 crore (up 140.3% YoY) while employee benefit expenses were at Rs 60.96 crore (down 10.9% YoY) during the period under review. Dr. Sanjeev Panchal, country president and managing director, AstraZeneca India, commented, 'We are pleased to report a strong financial performance this quarter. It reflects our continuous endeavour of harnessing science and commitment to bringing innovative medicines faster to India. We are focused on our ambition to ensure our therapies reach the patients who need them the most and are constantly working to tailor sustainable programs focused on early diagnosis and improved access to meet local needs by collaborating with healthcare systems, payers, policymakers, and non-government organizations.' Bhavana Agrawal, chief finance officer, added, It's a strong start of the year with 31% revenue growth and double-digit profit margin (before exceptional item and tax). The results are an outcome of company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years. We are continuously pushing the boundaries of science and are well positioned for consistent value creation for our customers and shareholders.' AstraZeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Powered by Capital Market - Live
Net loss of Astrazeneca Pharma India reported to Rs 11.79 crore in the quarter ended June 2024 as against net profit of Rs 53.86 crore during the previous quarter ended June 2023. Sales rose 31.15% to Rs 387.52 crore in the quarter ended June 2024 as against Rs 295.47 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales387.52295.47 31 OPM %9.8222.76 - PBDT46.3175.19 -38 PBT42.4071.40 -41 NP-11.7953.86 PL Powered by Capital Market - Live
Union Budget 2024: AstraZeneca set to gain from customs duty exemption on key cancer drugs in full Budget
![](https://pocket-image-cache.com/direct?url=http://akm-img-a-in.tosshub.com/businesstoday/images/story/202407/66a0c7e45e913-budget-2024--drugs-242242629-16x9.png)
Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live
Astrazeneca Pharma India announced that the Annual General Meeting (AGM) of the company will be held on 8 August 2024.Powered by Capital Market - Live
AstraZeneca Pharma Shares Plunge 14% To One-Month Low After Q3 Profit Dips 46%
![](https://pocket-image-cache.com/direct?url=http://media.assettype.com/bloombergquint%2F2024-02%2F30d59b92-5e68-42a8-b11a-b6831cda7603%2FAstraZeneca_Pharma_website.jpg?rect=0%2C6%2C620%2C326&w=1200&auto=format%2Ccompress&ogImage=true)
AstraZeneca Pharma India Plans To Sell Bengaluru Manufacturing Plant, Check Details - News18
![](https://pocket-image-cache.com/direct?url=http://images.news18.com/ibnlive/uploads/2023/11/astrazeneca-2023-11-7309df9509fe3a0a1b6ec52318c62f18-16x9.jpg?impolicy=website&width=1200&height=675)
Gift Nifty signals a tepid start: ITC, Vodafone Idea Q1 results; stocks in F&O ban; TVS Supply IPO & more
![](https://pocket-image-cache.com/direct?url=http://akm-img-a-in.tosshub.com/businesstoday/images/story/202308/29525db076bcc42505a356e55dbe94f38b28530b_getty-stock-market-data_1-sixteen_nine.jpg)
Stocks in news: ITC, Adani Ports, Tata Steel, Nykaa, Vodafone Idea, HDFC Bank & CarTrade
![](https://pocket-image-cache.com/direct?url=http://akm-img-a-in.tosshub.com/businesstoday/images/story/202308/36dfdfa1abbd0938fbd08a32d233fddf-sixteen_nine.jpg)
AstraZeneca Pharma shares gain on pediatric drug launch in India
![](https://pocket-image-cache.com/direct?url=http://images.moneycontrol.com/static-mcnews/2021/03/ASTRAZENECA-770x433.jpg)
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 12.58%, vs industry avg of 9.21%
Increasing Market Share
Over the last 5 years, market share increased from 0.33% to 0.36%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 24.29%, vs industry avg of 15.17%